Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives $19.40 Average PT from Brokerages
Shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV – Get Free Report) have earned an average recommendation of “Buy” from the six brokerages that are currently covering the stock, Marketbeat reports. Six analysts have rated the stock with a buy rating. The average 12-month price objective among analysts that have issued a report on the stock in […]
Shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV – Get Free Report) have earned an average recommendation of “Buy” from the six brokerages that are currently covering the stock, Marketbeat reports. Six analysts have rated the stock with a buy rating. The average 12-month price objective among analysts that have issued a report on the stock in […]
